Dialysis Machines

Introduction

Dialysis: removal of waste products and excess fluid from blood when kidneys fail. Patients: ~3.4 million worldwide on dialysis. Cost: $90,000/year per patient (US Medicare). Frequency: 3x/week for 3-4 hours (hemodialysis). Survival: 5-year survival ~40% (improved with better technology). Alternative: kidney transplant (preferred but donor shortage).

"Dialysis is a life-sustaining technology, yet it replaces only 10-15% of normal kidney function. The engineering challenge is enormous: filter 180 liters of blood daily, remove toxins while preserving essential molecules, all without damaging blood cells." -- Nephrologist

Kidney Function and Failure

Normal Kidney Functions

Filtration: 180 L/day filtered (99% reabsorbed). Waste removal: urea, creatinine, uric acid. Electrolyte balance: Na+, K+, Ca2+, PO4 regulation. Acid-base: bicarbonate reabsorption, H+ secretion. Fluid balance: regulate extracellular volume. Hormones: erythropoietin (RBC production), vitamin D activation, renin.

Chronic Kidney Disease (CKD)

Stages 1-2: kidney damage, normal GFR (>60 mL/min). Stage 3: moderate decrease (30-59 mL/min). Stage 4: severe decrease (15-29 mL/min). Stage 5: kidney failure (GFR <15 mL/min, dialysis needed). Causes: diabetes (44%), hypertension (29%), glomerulonephritis (7%), polycystic kidney disease (3%).

Uremia

Toxin accumulation: urea, creatinine, middle molecules. Symptoms: fatigue, nausea, confusion, pericarditis. Complications: anemia (low erythropoietin), bone disease (low vitamin D), cardiovascular disease. Indicator: BUN >100 mg/dL, creatinine >10 mg/dL typically requires dialysis.

Hemodialysis Principles

Diffusion

Principle: solutes move from high to low concentration across membrane. Rate: proportional to concentration gradient, membrane permeability, surface area. Small molecules (urea, MW 60): rapidly cleared. Middle molecules (beta-2-microglobulin, MW 11,800): slower clearance. Large molecules (albumin, MW 66,000): retained (should not cross membrane).

Ultrafiltration

Principle: pressure-driven water removal across membrane. Transmembrane pressure (TMP): blood side pressure - dialysate side pressure. Rate: typically 0.5-1.5 L/hour during session. Total removal: 1-4 L per session (excess fluid). Control: volumetric or gravimetric monitoring (precise to ±10 mL).

Convection

Principle: solute carried with water across membrane (solvent drag). Effect: enhances middle molecule removal. Hemodiafiltration (HDF): combines diffusion + convection. Advantage: better clearance of middle molecules. Evidence: may improve survival compared to standard hemodialysis.

Clearance Calculation

Clearance (K) = Qb × (Cin - Cout) / CinQb = blood flow rate (200-500 mL/min)Cin = inlet concentrationCout = outlet concentrationUrea clearance: 200-300 mL/min (typical)Creatinine clearance: 150-250 mL/minβ2-microglobulin: 20-80 mL/min

Dialyzer Design

Hollow-Fiber Configuration

Structure: ~10,000 hollow fibers (200 µm inner diameter). Blood: flows through fiber lumens. Dialysate: flows around fibers (countercurrent). Surface area: 1.0-2.5 m². Length: 20-25 cm. Material: synthetic membranes (polysulfone, polyethersulfone).

Countercurrent Flow

Blood direction: bottom to top. Dialysate direction: top to bottom (opposite). Advantage: maintains concentration gradient along entire length. Efficiency: 20-30% better than concurrent flow. Standard: all modern dialyzers use countercurrent.

Performance Characteristics

Membrane Technology

Membrane Materials

Cellulose-based: cuprophane (historical, activates complement). Modified cellulose: cellulose acetate (better biocompatibility). Synthetic: polysulfone, polyethersulfone, polyacrylonitrile (best biocompatibility). PMMA: polymethylmethacrylate (adsorptive properties). Current standard: synthetic membranes (>90% market share).

Pore Structure

Skin layer: asymmetric structure (dense layer on blood side, porous on dialysate side). Pore size: 1-10 nm (allows small molecules, rejects albumin). Molecular weight cutoff: ~65,000 Da (retain albumin MW 66,000). Sieving coefficient: 1.0 (freely permeable) to 0 (completely rejected). High-cutoff: ~50 kDa cutoff (emerging, removes larger toxins).

Biocompatibility

Complement activation: cellulose membranes cause significant activation (bioincompatible). Synthetic membranes: minimal complement activation. Leukocyte adhesion: reduced with synthetic membranes. Clinical impact: improved biocompatibility may reduce chronic inflammation. Modification: vitamin E coating, heparin grafting (further improvement).

Adsorptive Membranes

Mechanism: toxins bind to membrane surface (in addition to diffusion). Target: protein-bound toxins, cytokines (not removed by diffusion). Materials: PMMA, AN69 (polyacrylonitrile with sulfonate groups). Application: sepsis (cytokine removal), hepatorenal syndrome. Limitation: adsorption sites saturate (time-limited benefit).

Fluid and Electrolyte Management

Dialysate Composition

Sodium: 135-145 mEq/L (matched to plasma). Potassium: 0-4 mEq/L (adjusted based on patient levels). Calcium: 2.5-3.5 mEq/L. Bicarbonate: 32-40 mEq/L (correct acidosis). Glucose: 100-200 mg/dL (prevent hypoglycemia). Temperature: 35-37°C (cooler dialysate improves hemodynamic stability).

Sodium Modeling

Concept: vary dialysate sodium during session. High sodium early: prevents hypotension (maintains blood volume). Low sodium late: removes excess sodium. Profile: linear decrease from 148 to 138 mEq/L. Benefit: fewer intradialytic symptoms. Risk: may increase thirst and interdialytic weight gain.

Ultrafiltration Profiling

Constant rate: uniform removal throughout session. Stepped: high early, low late (removes fluid when better tolerated). Biofeedback: blood volume monitoring adjusts UF rate automatically. Goal: prevent intradialytic hypotension (most common acute complication).

Dry Weight Assessment

Definition: target weight after fluid removal (estimated euvolemia). Methods: clinical assessment (edema, blood pressure, jugular venous pressure). Bioimpedance: body composition analysis (extracellular water measurement). Lung ultrasound: B-lines indicate pulmonary congestion. Challenge: dry weight changes over time (weight gain/loss, muscle changes).

Vascular Access

Arteriovenous Fistula (AVF)

Preferred access: surgical connection of artery to vein (radiocephalic, brachiocephalic). Maturation: 6-12 weeks before use. Advantage: best longevity (years), lowest infection rate. Disadvantage: requires surgical planning, maturation time, may not develop adequately. Complication: steal syndrome (hand ischemia), aneurysm.

Arteriovenous Graft (AVG)

Synthetic conduit: PTFE graft connecting artery to vein. Use: 2-3 weeks after placement. Advantage: faster maturation than fistula. Disadvantage: higher infection and thrombosis rates. Lifespan: 2-3 years (shorter than AVF). Indication: patients with poor veins for fistula.

Central Venous Catheter (CVC)

Tunneled: Permcath (internal jugular vein), immediate use. Non-tunneled: temporary (days-weeks, femoral or internal jugular). Advantage: immediate access (no maturation). Disadvantage: highest infection rate (bacteremia), central venous stenosis. Use: bridge until permanent access matures, or when no other option.

Access Complications

Thrombosis: AVG > AVF > CVC (most common AVG complication). Infection: CVC > AVG > AVF (catheter-related bloodstream infection). Stenosis: venous outflow narrowing (requires angioplasty/stenting). Steal syndrome: hand ischemia from fistula diverting blood flow. Monitoring: flow measurements, physical exam, ultrasound surveillance.

Machine Components

Blood Circuit

Blood pump: roller pump (200-500 mL/min). Arterial line: from patient to dialyzer. Venous line: from dialyzer back to patient. Air detector: ultrasonic sensor prevents air embolism. Pressure monitors: arterial, venous, transmembrane. Blood leak detector: optical sensor detects hemoglobin in dialysate.

Dialysate Circuit

Water treatment: reverse osmosis + deionization (ultrapure water). Proportioning: concentrate + water mixed to final composition. Heating: temperature controlled (35-37°C). Degassing: removes dissolved air. Flow rate: 500-800 mL/min. Single-pass: used once, then discarded.

Safety Systems

Air detection: clamps line if air bubble detected. Blood leak: alarm if blood detected in dialysate. Pressure limits: alarms for high/low arterial/venous pressure. Conductivity: monitors dialysate composition continuously. Temperature: prevents thermal injury. Power failure: battery backup for blood return.

Water Treatment

Source: municipal water (must be purified). Pre-treatment: carbon filtration (remove chlorine), softening. Reverse osmosis: removes >95% of dissolved solids. Deionization: polishes to ultrapure (resistivity >1 MΩ-cm). Standards: AAMI (Association for Advancement of Medical Instrumentation). Volume: 120-150 L water per treatment (significant resource).

Peritoneal Dialysis

Principle

Dialysis membrane: peritoneum (natural membrane lining abdomen). Surface area: ~1-2 m² (comparable to dialyzer). Dialysate: instilled into peritoneal cavity through permanent catheter. Exchange: dwell time 4-8 hours (solute equilibration). Drain: gravity-assisted drainage before next fill.

Types

CAPD (Continuous Ambulatory PD): manual exchanges 4-5x daily. APD (Automated PD): cycler performs exchanges overnight. Hybrid: combination of CAPD and APD. Advantage: home-based, continuous (more physiologic). Disadvantage: peritonitis risk, protein loss, membrane failure over years.

Dialysate Solutions

Osmotic agent: dextrose (most common, 1.5%, 2.5%, 4.25%). Icodextrin: glucose polymer (for long dwell, better ultrafiltration). Amino acid solutions: provide nutrition (malnourished patients). Biocompatible solutions: neutral pH, low GDP (less peritoneal damage). Buffer: lactate or bicarbonate.

Complications

Peritonitis: infection of peritoneal cavity (0.5-1 episode/patient-year). Catheter complications: exit-site infection, malposition, obstruction. Membrane failure: encapsulating peritoneal sclerosis (rare, serious). Metabolic: hyperglycemia from dextrose absorption. Hernia: increased intra-abdominal pressure.

Dialysis Adequacy

Kt/V (Urea Kinetics)

K: dialyzer clearance (mL/min). t: treatment time (min). V: volume of distribution (body water, ~60% body weight). Target: Kt/V ≥ 1.4 per session (KDOQI guideline). Calculation: from pre/post-dialysis BUN, weight, treatment time. Significance: higher Kt/V associated with better outcomes.

Urea Reduction Ratio (URR)

Formula: (pre-BUN - post-BUN) / pre-BUN × 100%. Target: ≥ 65%. Simpler than Kt/V but less accurate (doesn't account for fluid removal). Application: quick assessment of treatment adequacy.

Beyond Small Solute Clearance

Middle molecules: β2-microglobulin, p-cresyl sulfate (toxicity independent of urea). Protein-bound toxins: not removed by conventional dialysis. Fluid management: volume control important (cardiovascular outcomes). Phosphorus control: dietary + dialysis + binders. Comprehensive assessment: beyond Kt/V alone.

Complications

Intradialytic Hypotension

Incidence: 20-30% of sessions. Mechanism: fluid removal exceeds plasma refilling rate. Prevention: sodium modeling, UF profiling, cooler dialysate. Treatment: Trendelenburg position, saline bolus, reduce UF rate. Impact: most common acute complication, limits fluid removal.

Cardiovascular Disease

Leading cause of death: ~50% of dialysis patients. Mechanism: chronic volume overload, mineral metabolism disorder, inflammation. LVH: left ventricular hypertrophy (almost universal). Calcification: vascular and cardiac valve calcification. Prevention: fluid management, phosphorus control, dialysis adequacy.

Dialysis Disequilibrium

Mechanism: rapid urea removal creates osmotic gradient (brain edema). Symptoms: headache, nausea, confusion, seizures. Risk: first dialysis treatment, very high BUN. Prevention: shorter, slower initial treatments. Treatment: slow dialysis, hypertonic saline if severe.

Long-Term Complications

Amyloidosis: β2-microglobulin deposition (arthropathy, carpal tunnel). Malnutrition: protein-energy wasting (common in dialysis). Anemia: reduced erythropoietin, iron deficiency. Bone disease: secondary hyperparathyroidism, adynamic bone disease. Depression: affects 20-30% of dialysis patients.

Emerging Technologies

Wearable Artificial Kidney

Concept: belt-mounted dialysis device (~5 kg). Continuous operation: 24/7 treatment (more physiologic). Sorbent technology: regenerates dialysate (reduces water requirement). Battery: rechargeable, 8-12 hours. Status: clinical trials (University of Washington). Impact: freedom of movement, improved quality of life.

Implantable Artificial Kidney

Silicon nanopore membrane: high-flux, biocompatible filter. Bioreactor: living renal tubule cells for reabsorption. Power: blood pressure-driven (no external battery). Size: coffee cup-sized implant. Status: preclinical development (Kidney Project). Promise: eliminate dialysis dependence.

Medium Cut-Off Membranes

Pore size: between high-flux and high-cutoff. Target: remove middle molecules while retaining albumin. Clinical: improved β2-microglobulin clearance. Evidence: REMOVAL-HD trial (promising early results). Adoption: growing use in expanded hemodialysis (HDx).

Home Hemodialysis

Simplified machines: NxStage System One (portable), Tablo (user-friendly). Frequency: short daily or nocturnal (more physiologic). Advantage: improved outcomes, quality of life, independence. Barrier: training, home modification, patient/partner burden. Trend: increasing adoption with simplified technology.

References

• Daugirdas, J. T., Blake, P. G., and Ing, T. S. (Eds.). "Handbook of Dialysis." Lippincott Williams & Wilkins, 5th ed., 2015.
• Clark, W. R., Hamburger, R. J., and Lysaght, M. J. "Effect of Membrane Composition and Structure on Solute Removal and Biocompatibility in Hemodialysis." Kidney International, vol. 56, no. 6, 1999, pp. 2005-2015.
• Davenport, A. "Dialysis Membranes." In Comprehensive Clinical Nephrology, 6th ed., Elsevier, 2019, pp. 1049-1058.
• Ronco, C., Clark, W. R. "Haemodialysis Membranes." Nature Reviews Nephrology, vol. 14, no. 6, 2018, pp. 394-410.
• Fissell, W. H., and Roy, S. "The Implantable Artificial Kidney." Seminars in Dialysis, vol. 22, no. 6, 2009, pp. 665-670.